Intellia's CRISPR Cuts Swelling; Sun Acquires Organon
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Intellia Therapeutics reported that a single dose of its CRISPR therapy lonvo‑z cut swelling attacks in a Phase 3 trial for hereditary angioedema, a rare disorder affecting ~20,000 patients in the U.S. and Europe.
- Intellia has begun a rolling FDA submission for lonvo‑z, aiming for the first in‑vivo CRISPR therapy approval after Vertex’s Casgevy.
- Sun Pharmaceutical agreed to buy Organon for $11.75 billion, financing the deal with cash and bank loans.
- Sun Pharma expects the acquisition to lift its 2025 revenue to $12.4 billion and place it among the top 25 global drugmakers.
Why it matters: Intellia gains an FDA‑approved CRISPR therapy, unlocking a new revenue stream while offering patients a one‑time cure; Sun Pharma gains $11.75 B of assets, boosting its 2025 revenue to $12.4 B and reshaping the global women’s‑health market.
